FDA Law Blog: Biosimilars

JANUARY 1, 2024

Four of the letters addressed failure to comply with drug Current Good Manufacturing Practice regulations, four more stated that the recipients were distributing unapproved drug products, two alleged violations of the Quality System Regulation by medical device manufacturers, and one was addressed to a clinical investigator.

FDA 59

FDA Clinical Trials FDA Compliance Production 59

Drug & Device Law

MARCH 19, 2024

TBI was the first nationwide (or close to it) analysis of whether a given jurisdiction permitted, under state law, a “warning”-based cause of action against a manufacturer of an FDA-regulated prescription drug or medical device for allegedly failing to report adverse events to the FDA. Brannon , 707 A.2d

FDA 52

FDA FDA Compliance Trials FDA Approval 52

Drug & Device Law

JANUARY 15, 2024

It is not evidence of the underlying attributes of the product that make it compliant with regulations or standards, which is presumably admissible subject to the ordinary Rules of Evidence. The OAJC’s view of standards compliance evidence, moreover, suggests that “door opening” may no longer be appropriate. Ethicon, Inc. ,

Compliance 52

Compliance Government FDA Compliance Production 52